Meet with... The National Cancer Institute SBIR Development Center

Add this event to your calendar:
12/04/2017 11:30 12/04/2017 19:00 America/Chicago Meet with... The National Cancer Institute SBIR Development Center JLABS @ TMC , John P. McGovern Campus , Houston , TX 77021 JLABS @ TMC false DD/MM/YYYY

Meet with... The National Cancer Institute SBIR Development Center

JLABS @ TMC , John P. McGovern Campus , Houston , TX 77021

April 12, 2017 from 11:30 AM to 19:00 PM (CST)

$10 - $35

The National Cancer Institute SBIR Development Center’s Team Leader and Program Director Dr. Greg Evans will present and discuss funding opportunities and resources available for small businesses with novel technologies that can prevent, diagnose, and treat cancer.
In this presentation, attendees will learn:

  • SBIR/STTR eligibility requirements
  • NIH SBIR/STTR process and new cancer-focused;grant funding opportunities from NCI
  • New NCI Funding Opportunities in priority research areas
  • NCI SBIR/STTR initiatives such as the expanded I-Corps™ at NIH Program
  • Practical strategies on how to successfully submit competitive research proposals

In addition, Dr. Evans will be holding one-on-one meetings with pre-approved companies. Please send a one-page (PDF preferred) executive summary to [email protected] by March 31st, 5PM ET.

9:30 AM | Registration Opens and Networking 
10:00 AM | Presentation and Q&A
11:00 AM | Networking Lunch
12:00-5:00 PM | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be approved. To be considered for a one-on-one meeting, please send a one-page (PDF preferred) executive summary to [email protected] by March 31st, 5PM ET.

National Cancer Institute Participating Representative:
Dr. Greg Evans | Team Leader and Program Director, Small Business Innovation Research Development Center, National Cancer Institute read bio»

About the National Cancer Institute:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Presentation & Lunch:
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until noon on April 11th (or sold out).

One-on-One Meetings:
FREE | Application
FREE | Accepted Companies
Please send a one-page (PDF preferred) executive summary to [email protected] by March 31st, 5PM ET to be considered for a one-on-one meeting.

About the Meet with... Series:

The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Thomas McNerney & Partners, NCATS, Poliwogg, and OrbiMed.

John P. McGovern Campus
2450 Holcombe Blvd, Suite J
Houston, TX 77021

Parking Information:
Please park in the self parking areas of the McGovern Campus. Grab a Token at the gate and bring it to the event space. We encourage carpooling and using the TMC shuttles.

National Cancer Institute Participating Representative's Biography:
Dr. Greg Evans | Team Leader and Program Director, Small Business Innovation Research Development Center, National Cancer Institute Greg

Dr. Greg Evans is a molecular biologist/biochemist by training who has worked at NIH for 26 years. He has 19 years experience as an NIH Program Director managing early-stage, bench-to-bedside (Translation I) research projects. Since June of 2008, Dr. Evans has served as a Team Leader and Program Director within the National Cancer Institute (NCI) SBIR Development Center, an office created in 2007 to centralize management of all NCI SBIR/STTR funding, to increase marketing efforts in the small business and biotechnology investment communities, and to raise the bar for commercialization of cancer-related products and services by small businesses. As a Team Leader, Dr. Evans leads a small group of 5 Program Directors responsible for small business projects in the imaging, cancer biology, and behavioral medicine areas. As a Program Director, he is responsible for a technically diverse portfolio that includes projects focused on imaging devices, drug development, diagnostics, basic cancer biology, and population-based cancer prevention. Prior to coming to the NCI SDC, Dr. Evans worked from 1998-2008 as a Program Director in the Blood Division of the National Heart, Lung, and Blood Institute (NHLBI) at NIH. In that capacity, he managed for five years the Comprehensive Sickle Cell Centers Clinical Trials Consortium, a 20-institution academic collaborative group funded to develop and implement collaborative Phase I-II clinical studies in sickle cell disease. Dr. Evans played a lead role coordinating and facilitating the development of 7 collaborative clinical studies. He also managed a joint NHLBI-Pfizer project for a Phase II/III contract clinical trial of Sildenafil (Viagra) for pulmonary hypertension secondary to sickle cell disease. In that effort, he played a key role in the development of an Independent Research Grant Agreement with Pfizer that covered donation of the study medication and matched placebo, as well as Pfizer’s special requirements for adverse event reporting. In addition, while with NHLBI Dr. Evans managed three projects under the NIH RAID (Rapid Access to Intervention Development) program, all of which involved both academic and commercial stakeholders. Lastly, he served on NHLBI-wide programs focused on Translation I research (e.g. Programs of Excellence in Gene Therapy, 2000-2005). Prior to moving to NHLBI to take a research administration position, Dr. Evans was a Senior Staff Fellow from 1995-1998 at the National Human Genome Research Institute at NIH, where he studied and published on gene therapy for the blood clotting disorder Hemophilia A. Before that, he served from 1991-1995 as a American Cancer Society postdoctoral fellow, and an intramural research and training fellow at the NCI, where he studied and published on MDR1-mediated multidrug resistance in cancer. Dr. Evans received a Ph.D. in Biochemistry in 1991 from the UCLA, and an undergraduate degree in Biochemistry from UC Berkeley in 1982. He is a native of Santa Rosa, California.
Connect with Greg: Connect on LinkedIn


Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to eight locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto and a ninth location, New York City, launching in 2018. For more information please visit

Event contact

Related content